X
XERS
Xeris Biopharma Holdings, Inc. Common Stock
$9.77
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Xeris Biopharma Holdings, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$0.11
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: $0.03
Nov 5
Posts
No posts about XERS yet.
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma is a Chicago-based drug company that develops and sells injectable and infusion medicines for rare and serious conditions. It earns money from three approved products: Recorlev, a treatment for Cushing's syndrome, a disorder caused by excess stress hormone, Gvoke, an emergency injection for severe low blood sugar, and Keveyis, a treatment for a rare seizure disorder. Recorlev has become the company's main growth engine over the past year.